{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:23Z","timestamp":1781835143344,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alcon Research"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ophtha.2018.10.040","type":"journal-article","created":{"date-parts":[[2018,11,4]],"date-time":"2018-11-04T09:36:05Z","timestamp":1541324165000},"page":"1095-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%\/Brimonidine 0.2%"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-4853","authenticated-orcid":false,"given":"Robert N.","family":"Weinreb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bacharach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Fechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Y.","family":"Kahook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Burmaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Hubatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.10.040_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/112067210801800517","article-title":"Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma","volume":"18","author":"Stewart","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-158-4-201302190-00008","article-title":"Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Boland","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2018.10.040_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archophthalmol.2010.20","article-title":"Delaying treatment of ocular hypertension: The Ocular Hypertension Treatment Study","volume":"128","author":"Kass","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ophtha.2018.10.040_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jop.2016.0141","article-title":"The 24-hour effects of brinzolamide\/brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure","volume":"33","author":"Seibold","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.10.040_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2012.0235","article-title":"Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%\/brimonidine 0.2%","volume":"29","author":"Nguyen","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.10.040_bib10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaophthalmol.2013.188","article-title":"Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%","volume":"131","author":"Katz","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/eye.2013.83","article-title":"Fixed-combination brinzolamide 1%\/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies","volume":"27","author":"Realini","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2018.10.040_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/eye.2016.126","article-title":"Ocular hypotensive effect of fixed-combination brinzolamide\/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial","volume":"30","author":"Fechtner","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2018.10.040_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ajo.2016.02.026","article-title":"A\u00a0randomized trial of fixed-dose combination brinzolamide 1%\/brimonidine 0.2% as adjunctive therapy to travoprost 0.004","volume":"165","author":"Feldman","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1167\/iovs.02-0666","article-title":"Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes","volume":"44","author":"Liu","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.10.040_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.124.6.793","article-title":"Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma","volume":"124","author":"Barkana","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib18","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1167\/iovs.03-0349","article-title":"Nocturnal elevation of intraocular pressure is detectable in the sitting position","volume":"44","author":"Liu","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.10.040_bib19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1167\/iovs.12-10709","article-title":"Twenty-four\u2013hour pattern of intraocular pressure in untreated patients with ocular hypertension","volume":"54","author":"Grippo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.10.040_bib20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ophtha.2010.03.026","article-title":"Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.10.040_bib21","first-page":"2460","article-title":"Ocular hypotensive efficacy of netarsudil ophthalmic solution 0.02% over a 24-hour period: a pilot study","volume":"58","author":"Peace","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.10.040_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajo.2004.04.022","article-title":"Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure","volume":"138","author":"Liu","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archophthalmol.2011.2573","article-title":"Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy","volume":"130","author":"Gulati","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ophtha.2008.09.054","article-title":"Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy","volume":"116","author":"Liu","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.10.040_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/IJG.0000000000000051","article-title":"Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension","volume":"23","author":"Fan","year":"2014","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2018.10.040_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajo.2016.04.019","article-title":"Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours","volume":"169","author":"Liu","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/eye.2011.239","article-title":"Twenty-four hour efficacy with the dorzolamide\/timolol-fixed combination compared with the brimonidine\/timolol-fixed combination in primary open-angle glaucoma","volume":"26","author":"Konstas","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2018.10.040_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICU.0b013e32831eef82","article-title":"Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings","volume":"20","author":"Leske","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2012.05.003","article-title":"24-hour intraocular pressure and ocular perfusion pressure in glaucoma","volume":"58","author":"Quaranta","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.10.040_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj\/eye\/6700053","article-title":"Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure","volume":"16","author":"Watts","year":"2002","journal-title":"Eye"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:07:19Z","timestamp":1758982039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018304664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0161642018304664"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.040","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%\/Brimonidine 0.2%","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}